Novel neuroprotective strategies in ischemic retinal lesions

International Journal of Molecular Sciences

Volumn 11, Issue 2, 2010, Pages 544-561

  Szabadfi, Krisztina ^a   Mester, Laszlo ^b   Reglodi, Dora ^a   Kiss, Peter ^a   Babai, Norbert ^a   Racz, Boglarka ^b   Kovacs, Krisztina ^b   Szabo, Aliz ^b   Tamas, Aliz ^a   Gabriel, Robert ^a   Atlasz, Tamas ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

^b UNIVERSITY OF PÉCS   (Hungary)

Author keywords

BCCAO; Diazoxide; Ischemia; PACAP; PARP inhibitor; Rat retina; Retinoprotection; Urocortin 2

Indexed keywords

ADENOSINE; ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA TOCOPHEROL; BASIC FIBROBLAST GROWTH FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR; BRIMONIDINE; CALCIUM CHANNEL BLOCKING AGENT; CANNABINOID; CARNITINE; CILIARY NEUROTROPHIC FACTOR; DIAZOXIDE; ERYTHROPOIETIN; ESTRADIOL; FLAVONOID; GLUTAMATE RECEPTOR ANTAGONIST; HO 3089; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; MORPHINE; NERVE GROWTH FACTOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PIGMENT EPITHELIUM DERIVED FACTOR; POTASSIUM CHANNEL BLOCKING AGENT; SCATTER FACTOR; SODIUM CHANNEL BLOCKING AGENT; SOMATOMEDIN B; UNCLASSIFIED DRUG; UROCORTIN I; UROCORTIN II; VASCULOTROPIN; XANTHOPHYLL;

ANTIOXIDANT ACTIVITY; APOPTOSIS; CAROTID ARTERY OBSTRUCTION; COMMON CAROTID ARTERY; COMPETITIVE INHIBITION; DIABETIC RETINOPATHY; DRUG MECHANISM; ISCHEMIC PRECONDITIONING; NEUROPROTECTION; NONHUMAN; RETINA INJURY; RETINA ISCHEMIA; RETINA MACULA AGE RELATED DEGENERATION; REVIEW;

BCCAO; DIAZOXIDE; ISCHEMIA; PACAP; PARP-INHIBITOR; RAT RETINA; RETINOPROTECTION; UROCORTIN 2;

ANIMALS; BENZIMIDAZOLES; DIAZOXIDE; DISEASE MODELS, ANIMAL; ISCHEMIA; NEUROPROTECTIVE AGENTS; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; RETINAL ARTERY OCCLUSION; UROCORTINS;

RATTUS;

EID: 77649211292     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms11020544     Document Type: Review

References (138)

1. Osborne, N.N.; Casson, R.J.; Wood, J.P.M.; Chidlow, G.; Graham, M.; Melena, J. Retinal ischemia: Mechanisms of damage and potential therapeutic strategies. Prog. Retin. Eye Res. 2004, 23, 91-147.
2. Harris, A.; Jonescu-Cuypers, C.P.; Kagemann, L.; Krieglstein, G.K. Atlas of Ocular Blood Flow-Vascular Anatomy, Pathophysiology, and Metabolism; Imprint of Butterworth Heinemann: Philadelphia, PA, USA, 2003.
3. Feigl, B. Age-related maculopathy-linking aetiology and pathophysiologycal changes to the ischaemia hypothesis. Prog. Retin. Eye Res. 2009, 28, 63-86.
4. Kaur, C.; Foulds W.S.; Ling, E.A. Blood-retinal barrier in hypoxic ischaemic conditions: basic concepts, clinical features and management. Prog. Retin. Eye Res. 2008, 27, 622-647.
5. Pournaras, C.J.; Rungger-Brandle, E.; Riva, C.E.; Hardarson, S.H.; Stefansson, E. Regulation of retinal blood flow in health and disease. Prog. Retin. Eye Res. 2008, 27, 284-330.
6. Chen, C.S.; Miller, N.R. Ocular ischemic syndrome: review of clinical presentations, etiology, investigation, and management. Compr. Ophthalmol. 2007, 8, 17-28.
7. Osborne, N.N.; Ugarte, M.; Chao, M.; Chidlow, G.; Bae, J.H.; Wood, J.P.; Nash, M.S. Neuroprotection in relation to retinal ischemia and relevance to glaucoma. Surv. Ophthalmol. 1999, 1, 102-128.
8. Bek, T. Inner retinal ischemia: current understanding and needs for further investigations. Acta Ophthalmol. 2009, 87, 362-367.
9. Roth, S. Endogenous neuroprotection in the retina. Brain Res. Bull. 2004, 62, 461-466.
10. Fulton, A.B.; Akula, J.D.; Mocko, J.A.; Hansen, R.M.; Benador, I.Y.; Beck, S.C.; Fahl, E.; Seeliger, M.W.; Moskowitz, A.; Harris, M.E. Retinal degenerative and hypoxic ischemic disease. Doc. Ophthalmol. 2009, 118, 55-61.
11. Kalesnykas, G.; Tuulos, T.; Uusitalo, H.; Jolkkonen, J. Neurogenereration and cellular stress in the retina and optic nerve in rat cerebral ischemia and hypoperfusion models. Neuroscience 2008, 55, 937-947.
12. Farkas, E.; Luiten, P.G.; Bari, F. Permanent, bilateral common carotid artery occlusion in the rat: A model for chronic cerebral hypoperfusion-related neurodegenerative diseases. Brain Res. Rev. 2007, 54, 162-180.
13. Slakter, J.S.; Spertus, A.D.; Weissman, S.S.; Henkind, P. An experimental model of carotid artery occlusive disease. Am. J. Ophtalmol. 1984, 97, 168-172.
14. Spertus, A.D.; Slakter, J.S.; Weissman, S.S.; Henkind, P. Experimental carotid occlusion: funduscopic and fluorescein angiographic findings. Br. J. Ophtalmol. 1984, 68, 47-57.
15. Block, F.; Schwarz, M.; Sontag, K.H. Retinal ischemia induced by occlusion of both common carotid arteries in rats as demonstrated by electroretinography. Neurosci. Lett. 1992, 144, 124-126.
16. Osborne, N.N.; Safa, R.; Nash, M.S. Photoreceptors are preferentially affected in the rat retina following permanent occlusion of the carotid arteries. Vision Res. 1999, 39, 3995-4002.
17. Stevens, W.D.; Fortin, T.; Pappas, B.A. Retinal and optic nerve degeneration after chronic carotid ligation. Stroke 2002, 33, 1107-1112.
18. Yamamoto, H.; Schmidt-Kasner, R.; Hamasaki, D.I.; Yamamoto, H.; Parel, J.M. Complex neurodegeneration in retina following moderate ischemia induced by bilateral common carotid artery occlusion in Wistar rats. Exp. Eye Res. 2006, 82, 767-779.
19. Lavinsky, D.; Arterni, N.S.; Achaval, M.; Netto, C.A. Chronic bilateral common carotid artery occlusion: a model for ocular ischemic syndrome in the rat. Graefe's Arch. Clin. Exp. Ophthalmol. 2006, 244, 199-204.
20. Mester, L.; Szabo, A.; Atlasz, T.; Szabadfi, K.; Reglodi, D.; Kiss, P.; Racz, B.; Tamas, A.; Gallyas, F.; Sumegi, B.; Hocsak, E.; Gabriel, R.; Kovacs, K. Protection against chronic hypoperfusion-induced retinal neurodegeneration by PARP inhibition via activation of PI3-kinase Akt pathway and suppression of JNK and p38 MAP kinases. Neurotox. Res. 2009, 18, 68-76.
21. Atlasz, T.; Babai, N.; Kiss, P.; Reglodi, D.; Tamas, A.; Szabadfi, K.; Toth, G.; Hegyi, O.; Lubics, A.; Gabriel, R. Pituitary adenylate cyclase activating polypeptide is protective in bilateral carotid occlusion-induced retinal lesion in rats. Gen. Comp. Endocrinol. 2007, 153, 108-114.
22. Vidal-Sanz, M.; Lafuente, M.; Sobrado-Calvo, P.; Selles-Navarro, I.; Rodriguez, E.; Mayor-Torroglosa, S.; Villegas-Perez, M.P. Death and neuroprotection of retinal ganglion cells after different types of injury. Neurotox. Res. 2000, 2, 215-227.
23. Dilsiz, N.; Sahaboglu, A.; Yildiz, M.Z.; Reichenbach, A. Protective effects of various antioxidants during ischemia-reperfusion in the rat retina. Graefe's Arch. Clin. Exp. Ophthalmol. 2006, 244, 627-633.
24. Li, S.Y.; Fu, Z.J.; Ma, H.; Jang, W.C.; So, K.F.; Wong, D.; Lo, A.C. Effect of lutein on retinal neurons and oxidative stress in a model of acute retinal ischemia/reperfusion. Invest. Ophthalmol. Vis. Sci. 2009, 50, 836-843.
25. Maher, P.; Hanneken, A. Flavonoids protect retinal ganglion cells from ischemia in vitro. Exp. Eye Res. 2008, 86, 366-374.
26. Roth, S.; Li, B.; Rosenbaum, P.S.; Gupta, H.; Goldstein, I.M.; Maxwell, K.M.; Gidday, J.M. Preconditioning provides complete protection against retinal ischemic injury in rats. Invest. Ophthalmol. Vis. Sci. 1998, 39, 777-785.
27. Obolensky, A.; Berenshtein, E.; Konijn, A.M.; Banin, E.; Chevion, M. Ischemic preconditioning of the rat retina: protective role of ferritin. Free Radic. Biol. Med. 2008, 44, 1286-1294.
28. Sakamoto, K.; Yonoki, Y.; Kuwagata, M.; Saito, M.; Nakahara, T.; Ishii, K. Histological protection against ischemia-reperfusion injury by early ischemic preconditioning in rat retina. Brain Res. 2004, 1015, 154-160.
29. Chollangi, S.; Wang, J.; Martin, A.; Quinn, J.; Ash, J.D. Preconditioning-induced protection from oxidative injury is mediated by leukemia inhibitory factor receptor (LIFR) and its ligands in the retina. Neurobiol. Dis. 2009, 34, 535-544.
30. Li, Y.; Roth, S.; Laser, M.; Ma, J.X.; Crosson, C.E. Retinal preconditioning and the induction of heat-shock protein 27. Invest. Ophthalmol. Vis. Sci. 2003, 44, 1299-1304.
31. Fernandez, D.C.; Chianelli, M.S.; Rosenstein, R.E. Involvement of glutamate in retinal protection against ischemia/reperfusion damage induced by post-conditioning. J. Neurochem. 2009, 111, 488-498.
32. Macaluso, C.; Frishman, L.J.; Frueh, B.; Kaelin-Lang, A.; Onoe, S.; Niemeyer, G. Multiple effects of adenosine in the arterially perfused mammalian eye. Possible mechanisms for the neuroprotective function of adenosine in the retina. Doc. Ophthalmol. 2003, 106, 51-59.
33. Tomita, H.; Ishiguro, S.; Abe, T.; Tamai, M. Administration of nerve growth factor, brain-derived neurotrophic factor and insulin-like growth factor-II protects phosphate-activated glutaminase in the ischemic and reperfused rat retinas. Tohoku J. Exp. Med. 1999, 187, 227-236.
34. Nishijima, K.; Ng, Y.-S.; Zhong, L.; Bradley, J.; Schubert, W.; Jo, N.; Akita, J.; Samuelsson, S.J.; Robinson, G.S.; Adamis, A.P.; Shima, D.T. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am. J. Pathol. 2007, 171, 53-67.
35. Sivilia, S.; Giuliani, A.; Fernández, M.; Turba, M.E.; Forni, M.; Massella, A.; de Sordi, N.; Giardino, L.; Calzà, L. Intravitreal NGF administration counteracts retina degeneration after permanent carotid artery occlusion in rat. BMC Neurosci. 2009, 10, 52.
36. Junk, A.K.; Mammis, A.; Savitz, S.I.; Singh, M.; Roth, S.; Malhotra, S.; Rosenbaum, P.S.; Cerami, A.; Brines, M.; Rosenbaum, D.M. Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc. Natl. Acad. Sci. USA 2002, 99, 10659-10664.
37. Dreixler, J.C.; Hagevik, S.; Hemmert, J.W.; Shaikh, A.R.; Rosenbaum, D.M.; Roth, S. Involvement of erythropoietin in retinal ischemic preconditioning. Anesthesiology 2009, 110, 774-780.
38. Jehle, T.; Meschede, W.; Dersch, R.; Feltgen, N.; Bach, M.; Lagreze, W.A. Erythropoietin protects retinal ganglion cells and visual function after ocular ischemia and optic nerve compression. Ophthalmologe 2009, in press.
39. Schmeer, C.; Gamez, A.; Tausch, S.; Witte, O.W.; Isenmann, S. Statins modulate heat shock protein expression and enhance retinal ganglion cell survival after transient retinal ischemia/reperfusion in vivo. Invest. Ophthalmol. Vis. Sci. 2008, 49, 4971-4981.
40. Russo, R.; Cavaliere, F.; Watanabe, C.; Nucci, C.; Bagetta, G.; Corasaniti, M.T.; Sakurada, S.; Morrone, L.A. 17Beta-estradiol prevents retinal ganglion cell loss induced by acute rise of intraocular pressure in rat. Prog. Brain Res. 2008, 173, 583-590.
41. El-Remessy, A.B.; Khalil, I.E.; Matragoon, S.; Abou-Mohamed, G.; Tsai, N.J.; Roon, P.; Caldwell, R.B.; Caldwell, R.W.; Green, K.; Liou, G.I. Neuroprotective effect of (-)Delta9-tetrahydrocannabinol and cannabidiol in N-methyl-D-aspartate-induced retinal neurotoxicity: involvement of peroxynitrite. Am. J. Pathol. 2003, 163, 1997-2008.
42. Riazi-Esfahani, M.; Kiumehr, S.; Asadi-Amoli, F.; Lashay, A.R.; Dehpour, A.R. Morphine pretreatment provides histologic protection against ischemia-reperfusion injury in rabbit retina. Retina 2008, 28, 511-517.
43. Riazi-Esfahani, M.; Kiumehr, S.; Asadi-Amoli, F.; Dehpour, A.R. Effects of intravitreal morphine administered at different time points after reperfusion in a rabbit model of ischemic retinopathy. Retina 2009, 29, 262-268.
44. Kocer, I.; Kulacoglu, D.; Altuntas, I.; Gundogdu, C.; Gullulu, G. Protection of the retina from ischemia-reperfusion injury by L-carnitine in guinea pigs. Eur. J. Ophthalmol. 2003, 13, 80-85.
45. Lombardi, G.; Moroni, F. Glutamate receptor antagonists protect against ischemia-induced retinal damage. Eur. J. Pharmacol. 1994, 271, 489-495.
46. Wood, J.P.; Schmidt, K.G.; Melena, J.; Chidlow, G.; Allmeier, H.; Osborne, N.N. The beta-adrenoceptor antagonists metipranolol and timolol are retinal neuroprotectants: comparison with betaxolol. Exp. Eye Res. 2003, 76, 505-516.
47. Donello, J.E.; Padillo, E.U.; Webster, M.L.; Wheeler, L.A.; Gil, D.W. Alpha(2)-Adrenoceptor agonists inhibit vitreal glutamate and aspartate accumulation and preserve retinal function after transient ischemia. J. Pharmacol. Exp. Ther. 2001, 296, 216-223.
48. Ettaiche, M.; Heurteaux, C.; Blondeau, N.; Borsotto, M.; Tinel, N.; Lazdunski, M. ATP-sensitive potassium channels [K(ATP)] in retina: a key role for delayed ischemic tolerance. Brain Res. 2001, 890, 118-129.
49. Sakamoto, K.; Kawakami, T.; Shimada, M.; Yamaguchi, A.; Kuwagata, M.; Saito, M.; Nakahara, T.; Ishii, K. Histological protection by cilnidipine, a dual L/N-type Ca(2+) channel blocker, against neurotoxicity induced by ischemia-reperfusion in rat retina. Exp. Eye Res. 2009, 88, 974-982.
50. Traustason, S.; Eysteinsson, T.; Agnarsson, B.A.; Stefánsson, E. GABA agonists fail to protect the retina from ischemia-reperfusion injury. Exp. Eye Res. 2009, 88, 361-366.
51. Holman, M.C.; Chidlow, G.; Wood, J.P.; Casson, R.J. Hyperglycemia rescues retinal neurons from hypoperfusion-induced injury. Invest. Ophthalmol. Vis. Sci. 2009, in press.
52. Fekete, É.M.; Zorrilla, E.P. Physiology, pharmacology, and therapeutic relevance of urocortins in mammals: Ancient CRF paralogs. Front. Neuroendocrinol. 2007, 28, 1-27.
53. Chen, A.; Perrin, M.; Brar, B.; Li, C.; Jamieson, P.; Digruccio, M.; Lewis, K.; Vale, W. Mouse corticotropin-releasing factor receptor type 2alpha gene: isolation, distribution, pharmacological characterization and regulation by stress and glucocorticoids. Mol. Endocrinol. 2005, 19, 441-458.
54. Latchman, D.S. Molecules in focus urocortin. Biochem. Cell Biol. 2002, 34, 907-910.
55. Pan, W.; Kastin, A.J. Urocortin and the brain. Prog. Neurobiol. 2008, 84, 148-156.
56. Skelton, K.H.; Owens, M.J.; Nemeroff, C.B. The neurobiology of urocortin. Regul. Pept. 2000, 93, 85-92.
57. Tsatsanis, C.; Androulidaki, A.; Dermitzaki, E.; Charalampopoulos, I.; Spiess, J.; Gravanis, A.; Margioris, A.N. Urocortin 1 and Urocortin 2 induce macrophage apoptosis via CRFR2. FEBS Lett. 2005, 579, 4259-4264.
58. Uchida, M.; Suzuki, M.; Shimizu, K. Effects of urocortin, corticotropin-releasing factor (CRF) receptor agonist, and astressin, CRF receptor antagonist, on the sleep-wake pattern: analysis by radiotelemetry in conscious rats. Biol. Pharm. Bull. 2007, 10, 1895-1897.
59. Brar, B.K.; Jonassen, A.K.; Egorina, E.M.; Chen, A.; Negro, A.; Perrin, M.H.; Mjøs, O.D.; Latchman, D.S.; Lee, K.F.; Vale, W. Urocortin-II and urocortin-III are cardioprotective against ischemia reperfusion injury: an essential endogenous cardioprotective role for corticotropin releasing factor receptor type 2 in the murine heart. Endocrinology 2004, 145, 24-35.
60. Liu, C.N.; Yang, C.; Liu, X.Y.; Li, S. In vivo protective effects of urocortin on ischemiareperfusion injury in rat heart via free radical mechanisms. Can. J. Physiol. Pharmacol. 2005, 83, 459-465.
61. Rademaker, M.T. Urocortin: cardiovascular actions and therapeutic implications. Lett. Drug Des. Discov. 2004, 1, 168-172.
62. Tao, J.; Li, S. Effects of UCN via ion mechanisms or CRF receptors? Biochem. Biophys. Res. Commun. 2005, 336, 731-736.
63. Facci, L.; Stevens, D.A.; Pangallo, M.; Franceschini, D.; Skaper, S.D.; Strijbos, P.J.L.M. Corticotropin-releasing factor (CRF) and related peptides confer neuroprotection via type 1 CRF receptors. Neuropharmacol 2003, 45, 623-636.
64. Pedersen, W.A.; Wan, R.; Zhang, P.; Mattson, M.P. Urocortin, but not urocortin II, protects cultured hippocampal neurons from oxidative and excitotoxic cell death via corticotropin-releasing hormone receptor type I. J. Neurosci. 2002, 22, 404-412.
65. Dautzenberg, F.M.; Huber, G.; Higelin, J.; Py-Lang, G.; Kilpatrick, G.J. Evidence for the abundant expression of arginine 185 containing human CRF2 receptors and the role of position 185 for receptor-ligand selectivity. Neuropharmacol. 2000, 39, 1368-1376.
66. Zmijewski, M.A.; Sharma, R.K.; Slominski, A.T. Expression of molecular equivalent of hypothalamic-pituitary-adrenal axis in adult retinal pigment epithelium. J. Endocrinol. 2007, 193, 157-169.
67. Skofitsch, G.; Jacobowitz, D.M. Corticotropin releasing factor-like immunoreactive neurons in the rat retina. Brain Res. Bull. 1984, 12, 539-542.
68. Williamson, D.E.; Eldred, W.D. Synaptic organization of two types of amacrine cells with CRF-like immunoreactivity in the turtle retina. Vis. Neurosci. 1991, 6, 257-269.
69. Williamson, D.E.; Eldred, W.D. Amacrine and ganglion cells with corticotropinreleasing-factor-like immunoreactivity in the turtle retina. J. Comp. Neurol. 1989, 280, 424-435.
70. Zhang, D.R.; Gallagher, M.; Sladek, C.D.; Yeh, H.H. Postnatal development of corticotrophin releasing factor-like immunoreactive amacrine cells in the rat retina. Brain Res. Dev. Brain Res. 1990, 51, 185-194.
71. Zhang, D.R.; Yeh, H.H. Corticotropin releasing factor-like immunoreactivity (CRFLI) in horizontal cells of the developing rat retina. Vis. Neurosci. 1991, 6, 383-391.
72. Zhang, D.R.; Yeh, H.H. Histogenesis of corticotropin releasing factor-like immunoreactive amacrine cells in the rat retina. Brain Res. Dev. Brain Res. 1990, 53, 194-199.
73. Szabadfi, K.; Atlasz, T.; Reglodi, D.; Kiss, P.; Danyáadi, B.; Fekete, É.M.; Zorrilla, E.P.; Tamas, A.; Szabo, K.; Gabriel, R. Urocortin 2 protects against retinal degeneration following bilateral common carotid artery occlusion in the rat. Neurosci. Lett. 2009, 455, 42-45.
74. Busija, D.W.; Lacza, Z.; Rajapakse, N.; Shimizu, K.; Kis, B.; Bari, F.; Domoki, F.; Horiguchi, T. Targeting mitochondrial ATP-sensitive potassium channels - a novel approach to neuroprotection. Brain Res. Rev. 2004, 46, 282-294.
75. Yamauchi, T.; Kashii, S.; Yasuyoshi, H.; Zhang, S.; Honda, Y.; Akaike, A. Mitochondrial ATP-sensitive potassium channel: a novel site for neuroprotection. Invest. Ophthalmol. Vis. Sci. 2003, 44, 2750-2756.
76. Domoki, F.; Perciaccante, J.V.; Veltkamp, R.; Bari, F.; Busija, D.W. Mitochondrial potassium channel opener diazoxide preserves neuronal-vascular function after cerebral ischemia in newborn pigs. Stroke 1999, 30, 2713-2718.
77. Liu, D.; Lu, C.; Wan, R.; Auyeung, W.W.; Mattson, M.P. Activation of mitochondrial ATP-dependent potassium channels protects neurons against ischemia-induced death by a mechanism involving suppression of Bax translocation and cytochrome c release. J. Cereb. Blood Flow Metab. 2002, 22, 431-443.
78. Minners, J.; McLeod, C.J.; Sack, M.N. Mitochondrial plasticity in classical ischemic preconditioning-moving beyond the mitochondrial KATP channel. Cardiovasc. Res. 2003, 59, 1-6.
79. Shake, J.G.; Peck, E.A.; Marban, E.; Gott, V.L.; Johnston, M.V.; Troncoso, J.C.; Redmond, J.M.; Baumgartner, W.A. Pharmacologically induced preconditioning with diazoxide: a novel approach to brain protection. Ann. Thorac. Surg. 2001, 72, 1849-1854.
80. Nagy, K.; Kis, B.; Rajapakse, N.C.; Bari, F.; Busija, D.W. Diazoxide preconditioning protects against neuronal cell death by attenuation of oxidative stress upon glutamate stimulation. J. Neurosci. Res. 2004, 76, 697-704.
81. Teshima, Y.; Akao, M.; Li, R.A.; Chong, T.H.; Baumgartner, W.A.; Johnston, M.V.; Marban, E. Mitochondrial ATP-sensitive potassium channel activation protects cerebellar granule neurons from apoptosis induced by oxidative stress. Stroke 2003, 34, 1796-1802.
82. Rajapakse, N.; Kis, B.; Horiguchi, T.; Snipes, J.; Busija, D.W. Diazoxide pretreatment induces delayed preconditioning in astrocytes against oxygen glucose deprivation and hydrogen peroxide-induced toxicity. J. Neurosci. Res. 2003, 73, 206-214.
83. Domoki, F.; Bari, F.; Nagy, K.; Busija, D.W.; Siklós, L. Diazoxide prevents mitochondrial swelling and Ca2+ accumulation in CA1 pyramidal cells after cerebral ischemia in newborn pigs. Brain Res. 2004, 1019, 97-104.
84. Kis, B.; Rajapakse, N.C.; Snipes, J.A.; Nagy, K.; Horiguchi, T.; Busija, D.W. Diazoxide induces delayed pre-conditioning in cultured rat cortical neurons. J. Neurochem. 2003, 87, 969-980.
85. Liu, Y.; Sato, T.; Seharaseyon, J.; Szewczyk, A.; O'Rourke, B.; Marban, E. Mitochondrial ATP-dependent potassium channels. Viable candidate effectors of ischemic preconditioning. Ann. NY Acad. Sci. 1999, 874, 27-37.
86. Shimizu, K.; Lacza, Z.; Rajapakse, N.; Horiguchi, T.; Snipes, J.; Busija, D.W. MitoK(ATP) opener, diazoxide, reduces neuronal damage after middle cerebral artery occlusion in the rat. Am. J. Physiol. Heart Circ. Physiol. 2002, 283, 1005-1011.
87. Busija, D.W.; Katakam, P.; Rajapakse, N.C.; Kis, B.; Grover, G.; Domoki, F.; Bari, F. Effects of ATP-sensitive potassium channel activators diazoxide and BMS-191095 on membrane potential and reactive oxygen species production in isolated piglet mitochondria. Brain Res. Bull. 2005, 66, 85-90.
88. Farkas, E.; Annahazi, A.; Institoris, A.; Mihaly, A.; Luiten, P.G.; Bari, F. Diazoxide and dimethyl sulphoxide alleviate experimental cerebral hypoperfusion-induced white matter injury in the rat brain. Neurosci. Lett. 2005, 373, 195-199.
89. Farkas, E.; Timmer, N.M.; Domoki, F.; Mihaly, A.; Luiten, P.G.; Bari, F. Post-ischemic administration of diazoxide attenuates long-term microglial activation in the rat brain after permanent carotid artery occlusion. Neurosci. Lett. 2005, 387, 168-172.
90. Lenzser, G.; Kis, B.; Bari, F.; Busija, D.W. Diazoxide preconditioning attenuates global cerebral ischemia-induced blood-brain barrier permeability. Brain Res. 2005, 1051, 72-80.
91. Farkas, E.; Institoris, A.; Domoki, F.; Mihaly, A.; Luiten, P.G.; Bari, F. Diazoxide and dimethyl sulphoxide prevent cerebral hypoperfusion-related learning dysfunction and brain damage after carotid artery occlusion. Brain Res. 2004, 1008, 252-260.
92. Farkas, E.; Institoris, A.; Domoki, F.; Mihaly, A.; Bari, F. The effect of pre- and posttreatment with diazoxide on the early phase of chronic cerebral hypoperfusion in the rat. Brain Res. 2006, 1087, 168-174.
93. Sheu, S.J.; Wu, S.N. Mechanism of inhibitory actions of oxidizing agents on calcium-activated potassium current in cultured pigment epithelial cells of the human retina. Invest. Ophthalmol. Vis. Sci. 2003, 44, 1237-1244.
94. Pielen, A.; Kirsch, M.; Hofmann, H.D.; Feuerstein, T.J.; Lagreze, W.A. Retinal ganglion cell survival is enhanced by gabapentin-lactam in vitro: evidence for involvement of mitochondrial KATP channels. Graefe's Arch. Clin. Exp. Ophthalmol. 2004, 242, 240-244.
95. Hankins, M.W.; Ikeda, H. Consequences of transient retinal hypoxia on rod input to horizontal cells in the rat retina. Vision Res. 1993, 33, 429-436.
96. Roth, S.; Dreixler, J.C.; Shaikh, A.R.; Lee, K.H.; Bindokas, V. Mitochondrial potassium ATP channels and retinal ischemic preconditioning. Invest. Ophthalmol. Vis. Sci. 2006, 47, 2114-2124.
97. Jehle, T.; Lagreze, W.A.; Blauth, E.; Knorle, R.; Schnierle, P.; Lucking, C.H.; Feuerstein, T.J. Gabapentin-lactam (8-aza-spiro[5,4]decan-9-on; GBP-L) inhibits oxygen glucose deprivation-induced [3H]glutamate release and is a neuroprotective agent in a model of acute retinal ischemia. Naunyn Schmiedebergs Arch. Pharmacol. 2000, 362, 74-81.
98. Atlasz, T.; Babai, N.; Reglodi, D.; Kiss, P.; Tamas, A.; Bari, F.; Domoki, F.; Gabriel, R. Diazoxide is protective in the rat retina against ischemic injury induced by bilateral carotid occlusion and glutamate-induced degeneration. Neurotox. Res. 2007, 12, 105-111.
99. Unoki, K.; La Vail, M.M. Protection of the rat retina from ischemic injury by brain-derived neurotrophic factor, ciliary neurotrophic factor, and basic fibroblast growth factor. Invest. Ophtalmol. Vis. Sci. 1994, 35, 907-915.
100. Ogata, N.; Wang, L.; Jo, N.; Tombran-Tink, J.; Takahashi, K.; Mrazek, D.; Matsumura, M. Pigment epithelium derived factor as a neuroprotective agent against ischemic retinal injury. Curr. Eye Res. 2001, 22, 245-252.
101. Shibuki, H.; Katai, N.; Kuroiwa, S.; Kurokawa, T.; Arai, J.; Matsumoto, K.; Nakamura, T.; Yoshimura, N. Expression and neuroprotective effect of hepatocyte growth factor in retinal ischemia-reperfusion injury. Invest. Ophthalmol. Vis. Sci. 2002, 43, 528-536.
102. Vaudry, D.; Falluel-Morel, A.; Bourgault, S.; Basille, M.; Burel, D.; Wurtz, O.; Fournier, A.; Chow, B.K.; Hashimoto, H.; Galas, L.; Vaudry, H. Pituitary adenylate cyclase activating polypeptide and its receptors: 20 years after the discovery. Pharmacol. Rev. 2009, 61, 283-357.
103. Ohtaki, H.; Nakamachi, T.; Dohi, K.; Shioda, S. Role of PACAP in ischemic neural death. J. Mol. Neurosci. 2008, 36, 16-25.
104. Somogyvari-Vigh, A.; Reglodi, D. Pituitary adenylate cyclase activating polypeptide: a potential neuroprotective peptide-review. Curr. Pharm. Des. 2004, 10, 2861-2889.
105. Seki, T.; Izumi, S.; Shioda, S.; Zhou, C.J.; Arimura, A.; Koide, R. Gene expression for PACAP receptor mRNA in the rat retina by in situ hybridization and in situ RT-PCR. Ann. N. Y. Acad. Sci. 2000, 921, 366-369.
106. Seki, T.; Shioda, S.; Ogino, D.; Nakai, Y.; Arimura, A.; Koide, R. Distribution and ultrastructural localization of a receptor for pituitary adenylate cyclase activating polypeptide and its mRNA in the rat retina. Neurosci. Lett. 1997, 238, 127-130.
107. Waschek, J.A. Multiple actions of pituitary adenylyl cyclase activating peptide in nervous system development and regeneration. Dev. Neurosci. 2002, 24, 14-23.
108. Bagnoli, P.; Dal Monte, M.; Casini, G. Expression of neuropeptides and their receptors in the developing retina of mammals. Histol. Histopathol. 2003, 18, 1219-1242.
109. Borba, J.C.; Henze, I.P.; Silveira, M.S.; Kubrusly, R.C.; Gardino, P.F.; de Mello, M.C.; Hokoc, J.N.; de Mello, F.G. Pituitary adenylate cyclase activating polypeptide (PACAP) can act as determinant of the tyrosine hydoxylase phenotype of dopaminergic cells during retina development. Dev. Brain Res. 2005, 156, 193-201.
110. Shoge, K.; Mishima, H.K.; Saitoh, T.; Ishihara, K.; Tamura, Y.; Shiomi, H.; Sasa, M. Attenuation by PACAP of glutamate-induced neurotoxicity in cultured retinal neurons. Brain Res. 1999, 839, 66-73.
111. Silveira, M.S.; Costa, M.R.; Bozza, M.; Linden, R. Pituitary adenylate cyclase activating polypeptide prevents induced cell death in retinal tissue through activation of cyclic AMP-dependent protein kinase. J. Biol. Chem. 2002, 277, 16075-16080.
112. Rabl, K.; Reglodi, D.; Banvolgyi, T.; Somogyvari-Vigh, A.; Lengvari, I.; Gabriel, R.; Arimura, A. PACAP inhibits anoxia-induced changes in physiological responses in horizontal cells in the turtle retina. Regul. Pept. 2002, 109, 71-74.
113. Seki, T.; Itoh, H.; Nakamachi, T.; Shioda, S. Suppression of ganglion cell death by PACAP following optic nerve transection in the rat. J. Mol. Neurosci. 2008, 36, 57-60.
114. Babai, N.; Atlasz, T.; Tamas, A.; Reglodi, D.; Toth, G.; Kiss, P.; Gabriel, R. Search for the optimal monosodium glutamate treatment schedule to study the neuroprotective effects of PACAP in the retina. Ann. N.Y. Acad. Sci. 2006, 1070, 149-155.
115. Babai, N.; Atlasz, T.; Tamas, A.; Reglodi, D.; Toth, G.; Kiss, P.; Gabriel, R. Degree of damage compensation by various PACAP treatments in monosodium glutamate-induced retinal degeneration. Neurotox. Res. 2005, 8, 227-233.
116. Tamas, A.; Gabriel, R.; Racz, B.; Denes, V.; Kiss, P.; Lubics, A.; Lengvari, I.; Reglodi, D. Effects of pituitary adenylate cyclase activating polypeptide in retinal degeneration induced by monosodium-glutamate. Neurosci. Lett. 2004, 372, 110-113.
117. Atlasz, T.; Szabadfi, K.; Reglodi, D.; Kiss, P.; Tamas, A.; Toth, G.; Molnar, A.; Szabo, K.; Gabriel, R. Effects of pituitary adenylate cyclase activating polypeptide (PACAP1-38) and its fragments on retinal degeneration induced by neonatal MSG treatment. Ann. NY Acad. Sci. 2009, 1163, 348-352.
118. Seki, T.; Nakatani, M.; Taki, C.; Shinonara, Y.; Ozawa, M.; Nishimura, S.; Shioda, S. Neuroprotective effect of PACAP against kainic acid (KA)-induced neurotoxicity in rat retina. Ann. NY Acad. Sci. 2006, 1070, 531-534.
119. Racz, B.; Tamas, A.; Kiss, P.; Toth, G.; Gasz, B.; Borsiczky, B.; Ferencz, A.; Gallyas, F. Jr.; Roth, E.; Reglodi, D. Involvement of ERK and CREB signalling pathways in the protective effect of PACAP on monosodium glutamate-induced retinal lesion. Ann. NY Acad. Sci. 2006, 1070, 507-511.
120. Racz, B.; Gallyas, F., Jr.; Kiss, P.; Toth, G.; Hegyi, O.; Gasz, B.; Borsiczky, B.; Ferencz, A.; Roth, E.; Tamas, A.; Lengvari, I.; Lubics, A.; Reglodi, D. The neuroprotective effects of PACAP in monosodium glutamate-induced retinal lesion involves inhibition of proapoptotic signaling pathways. Regul. Pept. 2006, 137, 20-26.
121. Racz, B.; Gallyas, F. Jr.; Kiss, P.; Tamas, A.; Lubics, A.; Lengvari, I.; Roth, E.; Toth, G.; Hegyi, O.; Verzar, Zs.; Fabricsek, Cs.; Reglodi D. Effects of pituitary adenylate cyclase activating polypeptide (PACAP) on the PKA-Bad-14-3-3 signaling pathway in glutamate-induced retinal injury in neonatal rats. Neurotox. Res. 2007, 12, 95-104.
122. Atlasz, T.; Szabadfi, K.; Kiss, P.; Tamas, A.; Toth, G.; Reglodi, D.; Gabriel, R. Evaluation of the protective effects of PACAP with cell-specific markers in ischemia-induced retinal degeneration. Brain Res. Bull. 2009, in press.
123. Virag, L.; Szabo, C. The therapeutic potential of poly(ADPribose) polymerase inhibitors. Pharmacol. Rev. 2002, 54, 375-429.
124. Pacher, P.; Szabo, C. Role of the peroxynitrite-poly(ADP-ribose) polymerase pathway in human disease. Am. J. Pathol. 2008, 173, 2-13.
125. Halmosi, R.; Berente, Z.; Osz, E.; Toth, K.; Literati-Nagy, P.; Sumegi, B. Effect of poly(ADP-ribose) polymerase inhibitors on the ischemia-reperfusion- induced oxidative cell damage and mitochondrial metabolism in Langendorff heart perfusion system. Mol. Pharmacol. 2001, 59, 1497-1505.
126. Hong, S.J.; Dawson, T.M.; Dawson, V.L. Nuclear and mitochondrial conversations in cell death: PARP-1 and AIF signaling. Trends Pharmacol. Sci. 2004, 25, 259-264.
127. Yu, S.W.; Wang, H.; Poitras, M.F.; Coombs, C.; Bowers, W.J.; Federoff, H.J.; Poirier, G.G.; Dawson, T.M.; Dawson, V.L. Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science 2002, 297, 259-263.
128. Xu, Y.; Huang, S.; Liu, Z.G.; Han, J. Poly(ADP-ribose) polymerase-1 signaling to mitochondria in necrotic cell death requires RIP1/TRAF2-mediated JNK1 activation. J. Biol. Chem. 2006, 281, 8788-8795.
129. Veres, B.; Gallyas, F. Jr.; Varbiro, G.; Berente, Z.; Osz, E.; Szekeres, G.; Szabo, C.; Sumegi, B. Decrease of the inflammatory response and induction of the Akt/protein kinase B pathway by poly-(ADP-ribose) polymerase 1 inhibitor in endotoxin-induced septic shock. Biochem. Pharmacol. 2003, 65, 1373-1382.
130. Weise, J.; Isenmann, S.; Bahr, M. Increased expression and activation of poly(ADP-ribose) polymerase (PARP) contribute to retinal ganglion cell death following rat optic nerve transection. Cell Death Differ. 2001, 8, 801-807.
131. Paquet-Durand, F.; Silva, J.; Talukdar, T.; Johnson, L.E.; Azadi, S.; van Veen, T.; Ueffing, M.; Hauck, S.M.; Ekstrom, P.A. Excessive activation of poly-(ADP-ribose) polymerase contributes to inherited photoreceptor degeneration in the retinal degeneration 1 mouse. Neurobiol. Dis. 2007, 27, 10311-10319.
132. Li, G.Y.; Osborne, N.N. Oxidative-induced apoptosis to an immortalized ganglion cell line is caspase independent but involves the activation of poly (ADP-ribose) polymerase and apoptosisinducing factor. Brain Res. 2008, 1188, 35-43.
133. Goebel, D.J.; Winkler, B.S. Blockade of PARP activity attenuates poly(ADP-ribosyl)ation but offers only partial neuroprotection against NMDA-induced cell death in the rat retina. J. Neurochem. 2006, 98, 1732-1745.
134. Uehara, N.; Miki, K.; Tsukamoto, R.; Matsuoka, Y.; Tsubura, A. Nicotinamide blocks N-methyl-N-nitrosourea-induced photoreceptor cell apoptosis in rats through poly (ADP-ribose) polymerase activity and Jun N-terminal kinase/activator protein-1 pathway inhibition. Exp. Eye Res. 2006, 82, 488-495.
135. Ferrer, I.; Planas, A.M. Signaling of cell death and cell survival following focal cerebral ischemia: life and death struggle in the penumbra. J. Neuropathol. Exp. Neurol. 2003, 62, 329-339.
136. Meli, E.; Pangallo, M.; Baronti, R.; Chiarugi, A.; Cozzi, A.; Pellegrini-Giampietro, D.E.; Moroni, F. Poly(ADP-ribose) polymerase as a key player in excitotoxicity and post-ischemic brain damage. Toxicol. Lett. 2003, 139, 153-162.
137. Ikeda, Y.; Hokamura, K.; Kawai, T.; Ishiyama, J.; Ishikawa, K.; Anraku, T.; Uno, T.; Umemura, K. Neuroprotective effects of KCL-440, a new poly(ADP-ribose) polymerase inhibitor, in the rat middle cerebral artery occlusion model. Brain Res. 2005, 1060, 73-80.
138. Cozzi, A.; Cipriani, G.; Fossati, S.; Faraco, G.; Formentini, L.; Min, W.; Cortes, U.; Wang, Z.Q.; Moroni, F.; Chiarugi, A. Poly(ADPribose) accumulation and enhancement of postischemic brain damage in 110-kDa poly(ADP-ribose) glycohydrolase null mice. J. Cereb. Blood Flow Metab. 2006, 26, 684-695.